Daily peanuts for fullness, diet quality, and body composition
Official title: Dietary Peanut Intake and Nutrition-Related Outcomes in Individuals Using GLP-1 Receptor Agonists: A Randomized Controlled Trial
Run by University Hospitals Cleveland Medical Center · NCT07244458 · Data updated 2026-11-12
This study will test whether eating peanuts every day for 12 weeks helps adults taking GLP‑1 medicines feel fuller, have more energy, and improve weight and body composition.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 64 (estimated) |
| Sponsor | University Hospitals Cleveland Medical Center Academic / other |
| Locations | 1 site (Clevland, Ohio) |
| Status | Recruiting |
| Started | April 20, 2026 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | April 23, 2026 |
| Trial ID | NCT07244458 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with at least one weight-related comorbidity who have been taking semaglutide or tirzepatide for at least six months, are not allergic to nuts, and can attend in-person visits in Cleveland, Ohio.
✕Probably not a fit
People with a known nut allergy, those not using or with contraindications to GLP‑1 receptor agonists, pregnant or breastfeeding individuals, and incarcerated persons are excluded and would not receive benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study enrolls adults with obesity or overweight plus a weight-related comorbidity who have been using semaglutide or tirzepatide for at least six months. Participants will add a daily portion of peanuts to their meals for 12 weeks and undergo body composition assessment by DEXA, blood tests, and questionnaires on satiety, energy, and eating enjoyment. Investigators will track changes in weight-related outcomes, dietary quality, and selected health markers. The aim is to see if peanuts can boost fullness and overall nutrition without undermining weight management in people already on GLP‑1 receptor agonists.
Why it matters
Potential benefit: If successful, adding daily peanuts could increase satiety and improve diet quality and body composition for adults taking GLP‑1 medications.
How similar studies have gone: Previous trials of daily nut consumption have often shown improved satiety and diet quality without causing weight gain, but applying this approach specifically to people on GLP‑1 medications is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals with a BMI ≥30 kg/m2 or with a BMI ≥27 kg/m2 with at least one weight-related comorbidity who have been using semaglutide or tirzepatide for a clinical indication or at least 6 months Exclusion Criteria: * No use or contraindication to use of a GLP-1 RA * Known allergy to nuts * Pregnant or breastfeeding * Incarcerated
Where it's running
-
University Hospitals Cleveland Medical Center
Clevland, Ohio, United States Recruiting
Study contacts
- Principal investigator: Ian Neeland, MD — University Hospitals Cleveland Medical Center
- Study coordinator: Ian Neeland, MD
- Email: Ian.Neeland@UHhospitals.org
- Phone: 216-844-5965
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Daily pistachios for people taking GLP-1 weight-loss medicines
This 12-week test will see if eating pistachios every day helps adults on GLP-1 medicines feel fuller, have more energy, and improve weight and diet quality.
-
How incretin treatments affect muscle mass and function in people with overweight or obesity
This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.
-
Dose find for remimazolam plus alfentanil for gastroscopy in obese adults
This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.
-
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults
This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.
-
Gut barrier and inflammation after fast-food overfeeding in adults
This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.